drugset / Trial / NCT02886299

Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis

NCT02886299

Phase 4 Completed 60 enrolled Cairo University
RandomizedParallel-groupOpen-labelTreatment

Summary

Sixty chronic hemodialysis patients were randomly assigned to receive fenofibrate 100 mg (group 1, n = 30) or simvastatin 20 mg (group 2, n = 30) three times/week after their dialysis session. The safety and efficacy of drugs on lipid profile, oxidized low density lipoproteins (ox-LDL), glutathione peroxidase (GSH-Px) and C-reactive protein (CRP) were compared before and after 16-week treatment.

Timeline

Start
2013-10
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fenofibrate Small molecule 100 mg Oral
Comparator Simvastatin Small molecule 20 mg Oral

Indications

No indication recorded.